Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aspirin for maintenance of hemodialysis graft patency in adults with end-stage renal disease
IRCT20200530047604N1Phase 3Completed
- Sponsor
- Zanjan University of Medical Sciences
- Start
- Apr 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of aspirin in end-stage kidney disease (ESKD) (2 arms), sponsored by Zanjan University of Medical Sciences. Primary endpoints: Graft patency and Obstruction problems. Started Apr 2021; status: completed.
02
Drugs
aspirin
03
Conditions
end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on IRCT20200530047604N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200530047604N1.